Which of the following medications—bupropion (Wellbutrin), valproic acid (Depakote), or the unrecognized drug cobenfy—is most likely to cause weight gain?

Depakote (Valproic Acid) Has the Highest Risk of Weight Gain

Among the three medications, Depakote (valproic acid) carries the highest risk of weight gain, while Wellbutrin (bupropion) is actually associated with weight loss, and Cobenfy is a newer medication with limited weight data.

Weight Gain Risk by Medication

Depakote (Valproic Acid) - HIGHEST RISK

• Valproic acid is robustly associated with significant weight gain in both adults and children 1, 2, 3
• Weight gain typically occurs within the first 3 months of therapy, with women appearing more susceptible than men 3
• A meta-analysis demonstrated that valproic acid causes approximately 1.8-2.8 kg of weight gain in clinical trials 2
• An increase of 2 kg body weight after just 1 month of treatment should prompt consideration to change therapy 3

Clinical Pitfall: The weight gain with valproic acid can lead to insulin resistance and other metabolic abnormalities, making early monitoring critical 3

Wellbutrin (Bupropion) - WEIGHT LOSS

• Bupropion is the only antidepressant consistently associated with weight loss rather than weight gain 4, 5
• In clinical trials, 23% of patients lost ≥5 lbs compared to only 11% on placebo 4
• FDA-approved data shows that 14-19% of patients on bupropion sustained-release lost >5 lbs at 6 months, compared to only 6% on placebo 6
• A large comparative study found bupropion resulted in 0.22 kg less weight gain compared to sertraline at 6 months, with 15% reduced risk of gaining ≥5% baseline weight 5
• Meta-analysis confirmed bupropion causes approximately 1.3 kg weight loss 2

Cobenfy (Xanomeline + Trospium) - LIMITED DATA

• Cobenfy is a recently approved combination medication for schizophrenia, combining xanomeline (a muscarinic agonist) with trospium (to reduce peripheral side effects) 7
• No specific weight gain data is available in the provided evidence for Cobenfy as a standalone consideration
• The medication represents a novel mechanism distinct from traditional antipsychotics, but weight effects require further study 7

Clinical Algorithm for Weight-Conscious Prescribing

When Weight Gain is a Concern:

1. Avoid Depakote - Consider alternative mood stabilizers or anticonvulsants with lower weight gain risk 1, 3
2. Consider Wellbutrin - If treating depression or as adjunctive therapy, bupropion actively promotes weight loss 8, 4
3. Monitor Early - Measure baseline weight before starting any of these medications, then monthly for the first 3 months 3

Important Contraindications for Bupropion:

• Seizure disorders or conditions lowering seizure threshold 6
• Eating disorders (anorexia nervosa or bulimia) 6
• Abrupt discontinuation of alcohol, benzodiazepines, or barbiturates 6

Key Caveat: While bupropion promotes weight loss, it can be activating and may exacerbate anxiety, requiring assessment of anxiety levels before prescribing 9